There's a strong case that healthcare is the most important sector in the stock market. Investors stand to benefit as ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Yeztug (lenacapavir), an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) to reduce the risk of ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Krystal's Vyjuvek innovative gene therapy leads DEB treatment, overshadowing Abeona's Zevaskyn. Check out the comparison ...

FDA approves cell-sheet-based gene therapy for severe skin disease Download PDF. NEWS IN BRIEF; 07 May ... (Vyjuvek), a topical, redosable gene therapy that the FDA approved for DEB in 2023.